# BetaGlue Therapeutics: Medical devices, Milan, Italy

> BetaGlue Therapeutics: BetaGlue Therapeutics is an Italian clinical-stage oncology company based in Milan. Based in Milan, Italy. Founded 2016.

Source: https://millionrounds.com/startup/betaglue-therapeutics (Millionrounds; every figure on the page links to its filing or article)

Italy · [Medical devices startup](https://millionrounds.com/companies)

# BetaGlue Therapeutics

BetaGlue Therapeutics is an Italian clinical-stage oncology company based in Milan.

Email

Funding reported Last round: Undisclosed round

Medical devices Milan, Italy

Follow BetaGlue Therapeutics and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fbetaglue-therapeutics)

Company summary

- **Founded:** 2016 10 years old
- **Team:** 23 11 to 50 people
- **Funding reported:** 28M as listed, currency not stated
- **Last round:** Undisclosed round Jun 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for BetaGlue Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About BetaGlue Therapeutics

BetaGlue Therapeutics is an Italian clinical-stage oncology company based in Milan.

Founded in 2009, the company focuses on developing targeted nuclear therapies for unresectable solid tumors. Its lead product, YntraDose®, is designed for the localized treatment of pancreatic cancer, specifically unresectable locally advanced pancreatic cancer. YntraDose® utilizes a proprietary radiotherapy platform that delivers radiation directly into tumors using Yttrium-90 microspheres embedded in a biocompatible glue. This targeted delivery method minimizes off-target effects and enhances treatment efficacy. BetaGlue Therapeutics is committed to transforming nuclear science into effective cancer treatments, aiming to set a new standard of care in radiotherapy. The company is actively developing personalized radiotherapy solutions and has received regulatory approval for clinical trials in the UK.

## What company datasets say BetaGlue Therapeutics raised

Funding, as reported

Reported in all **28M** in the source's currency

Rounds **4**

Last round **Undisclosed round**

Last round size **6.6M**

Last round date **Jun 2024**

Investors listed **9**

## Founders and team

From BetaGlue Therapeutics's own website: 7 on the team.

- **Salvatore Calabrese** Chief Financial Officer (CFO)
- **Dr. Carol Hegarty** Head of Clinical Operations
- **Dr. Pieter Janssen** Head of Product Development
- **Francesco Berri** Head of M&A & Business Development at LIFTT
- **Pietro Bubba Bello** Head of Manufacturing & Operations
- **Alexis Peyroles** Chairman Inside Tx & OWL Life Sciences
- **Mike Cogswell** Chairman of DermaCure RT & EbaMed SA

## The company, in detail

What they build

Known for

treatment efficacy health care biocompatible bioglue organ preservation interventional radiology single session radiotherapy intratumoral injection oncology innovation pancreas imaging guidance medical equipment manufacturing cancer patient groups personalized cancer treatment percutaneous radiotherapy hospital & health care medical

Built with from their website

Yoast SEO Google Maps Contact Form 7 WordPress.org Font Awesome CloudFlare Viewport Meta Visual Composer Yoast Element UI

+8 more

Google Maps (Non Paid Users) Wordpress Microsoft Exchange Online jQuery Migrate Redux Framework cdnjs Priority Hints CAPTCHA

- **Sector:** Medical devices
- **Industry code:** NAICS 541714, 339112, SIC 8731
- **Region:** Lombardy
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/betaglue-technologies)

## Medical devices in Italy

Startups like it

- [**GreenBone Ortho** Roncadelle · founded 2015 *Raised*](https://millionrounds.com/company/greenbone-ortho)
- [**InnovHeart** Milan · founded 2015](https://millionrounds.com/startup/innovheart)
- [**WISE SpA** Cologno Monzese · founded 2011](https://millionrounds.com/startup/wise-spa)
- [**Prothea Technologies** Milan](https://millionrounds.com/startup/prothea-technologies)
- [**DIALYBRID** Cantu · founded 2020](https://millionrounds.com/startup/dialybrid)
- [**INTRAUMA S.P.A.** Rivoli · founded 2006](https://millionrounds.com/startup/intrauma-s-p-a)
- [**Newronika S.p.A.** Cologno Monzese · founded 2016](https://millionrounds.com/startup/newronika-s-p-a)
- [**KLISBio** Bresso · founded 2014](https://millionrounds.com/startup/klisbio)

## Is this your company?

Add your raise, your deck and your story, and put BetaGlue Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)